The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma

Neoplasia

Volumn 11, Issue 11, 2009, Pages 1155-1164

  Cesca, Marta ^a   Frapolli, Roberta ^a   Berndt, Alexander ^b   Scarlato, Valentina ^a   Richter, Petra ^b   Kosmehl, Hartwig ^c   D'Incalci, Maurizio ^a   Ryan, Anderson J ^d   Giavazzi, Raffaella ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c HELIOS KLINIKUM ERFURT   (Germany)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; HOE 33342; PACLITAXEL; SMOOTH MUSCLE ACTIN; VANDETANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TUMOR LEVEL; FEMALE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CARCINOMA; PERFUSION; PERITONEUM METASTASIS; PRIORITY JOURNAL; STAINING; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WEIGHT REDUCTION;

EID: 70350726336     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09866     Document Type: Article

References (49)

1. Folkman J (2003). Fundamental concepts of the angiogenic process. Curr Mol Med 3, 643-651.
2. Folkman J (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6, 273-286.
3. Yu JL, Coomber BL, and Kerbel RS (2002). A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation 70, 599-609.
4. El Emir E, Qureshi U, Dearling JL, Boxer GM, Clatworthy I, Folarin AA, Robson MP, Nagl S, Konerding MA, and Pedley RB (2007). Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. Cancer Res 67, 11896-11905.
5. Taraboletti G and Margosio B (2001). Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol 1, 378-384.
6. Ferrara N and Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature 438, 967-974.
7. Gasparini G, Longo R, Fanelli M, and Teicher BA (2005). Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23, 1295-1311. (Pubitemid 46202288)
8. Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V, and Ran S (2008). Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 10, 613-623. (Pubitemid 351770305)
9. Ferrara N, Hillan KJ, Gerber HP, and Novotny W (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3, 391-400. (Pubitemid 38618122)
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342. (Pubitemid 38702844)
11. Giavazzi R, Bani MR, and Taraboletti G (2007). Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer Metastasis Rev 26, 481-488. (Pubitemid 350115104)
12. Teicher BA (1996). A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics → mechanism(s) of interaction). Cancer Metastasis Rev 15, 247-272.
13. Minchinton AI and Tannock IF (2006). Drug penetration in solid tumours. Nat Rev Cancer 6, 583-592.
14. McDonald DM and Choyke PL (2003). Imaging of angiogenesis: from microscope to clinic. Nat Med 9, 713-725.
15. Thorpe PE (2004). Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10, 415-427. (Pubitemid 38173977)
16. Baluk P, Hashizume H, and McDonald DM (2005). Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15, 102-111. (Pubitemid 40127638)
17. Jain RK (2001). Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7, 987-989.
18. Hagendoorn J, Tong R, Fukumura D, Lin Q, Lobo J, Padera TP, Xu L, Kucherlapati R, and Jain RK (2006). Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res 66, 3360-3364.
19. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
20. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, and van Oosterom AT (2003). Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88, 1979-1986. (Pubitemid 36829677)
21. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, et al. (2004). Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563. (Pubitemid 40017699)
22. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, and Jain RK (2004). Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64, 3731-3736. (Pubitemid 38697278)
23. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, and Davidoff AM (2007). Bevacizumabinduced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13, 3942-3950. (Pubitemid 47037602)
24. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, and Kerbel RS (2006). Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 66, 3639-3648.
25. Ellis LM and Hicklin DJ (2008). VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 8, 579-591.
26. Smith JK, Mamoon NM, and Duhe RJ (2004). Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol Res 14, 175-225.
27. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26, 127-132.
28. Ma J and Waxman DJ (2008). Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7, 3670-3684.
29. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, et al. (2002). ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62, 4645-4655. (Pubitemid 34898591)
30. Ciardiello F, Caputo R, Damiano V, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, and Tortora G (2003). Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9, 1546-1556. (Pubitemid 36418413)
31. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, et al. (2007). Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6, 471-483. (Pubitemid 46332449)
32. Yano S, Muguruma H, Matsumori Y, Goto H, Nakataki E, Edakuni N, Tomimoto H, Kakiuchi S, Yamamoto A, Uehara H, et al. (2005). Antitumor vascular strategy for controlling experimental metastatic spread of human smallcell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Clin Cancer Res 11, 8789-8798. (Pubitemid 43005930)
33. Beaudry P, Nilsson M, Rioth M, Prox D, Poon D, Xu L, Zweidler-Mckay P, Ryan A, Folkman J, Ryeom S, et al. (2008). Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther 7, 418-424. (Pubitemid 351302535)
34. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, and Wedge SR (2004). ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10, 8587-8593. (Pubitemid 40053426)
35. Troiani T, Lockerbie O, Morrow M, Ciardiello F, and Eckhardt SG (2006). Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther 5, 1883-1894. (Pubitemid 44323257)
36. Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, et al. (2006). Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 12, 7099-7107. (Pubitemid 44974510)
37. Gustafson DL, Frederick B, Merz AL, and Raben D (2008).Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 61, 179-188.
38. Herbst RS, Heymach JV, O'Reilly MS, Onn A, and Ryan AJ (2007). Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16, 239-249. (Pubitemid 46206638)
39. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, et al. (2008). Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26, 5407-5415.
40. Markman M (2008). Pharmaceutical management of ovarian cancer: current status. Drugs 68, 771-789. (Pubitemid 351550530)
41. Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA, Liu ET, and Giavazzi R (2004). Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 3, 111-121. (Pubitemid 39193685)
42. Manenti L, Riccardi E, Marchini S, Naumova E, Floriani I, Garofalo A, Dossi R, Marrazzo E, Ribatti D, Scanziani E, et al. (2005). Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther 4, 715-725. (Pubitemid 40767115)
43. Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, and Giavazzi R (2006). The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin Cancer Res 12, 1839-1849.
44. Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, Long M, Morrow M, Ciardiello F, and Eckhardt SG (2007). Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res 13, 6450-6458. (Pubitemid 350075035)
45. Hlatky L, Hahnfeldt P, and Folkman J (2002). Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94, 883-893. (Pubitemid 34778087)
46. Hicklin DJ (2007). Promoting angiogenesis to a fault. Nat Biotechnol 25, 300-302.
47. Smith KA, Hill SA, Begg AC, and Denekamp J (1988). Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 57, 247-253.
48. Czabanka M, Vinci M, Heppner F, Ullrich A, and Vajkoczy P (2009). Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. Int J Cancer 124, 1293-1300.
49. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, et al. (2008). Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 198, 477.e471-477.e479; discussion 477.e479-477.e410.